Intelligence Feed event · Equity · 2026-09-09

    DENTSPLY SIRONA Beats Q2 Adjusted EPS at $0.52 and Reaffirms Guidance

    Question

    DENTSPLY SIRONA Beats Q2 Adjusted EPS at $0.52 and Reaffirms Guidance

    Direct answer

    DENTSPLY SIRONA delivered a solid bottom-line performance in Q2, with adjusted EPS reaching $0.52 against the $0.36 expected by analysts. Cost controls and segment performance bolstered profitability. Consolidated revenue contracted by 4.1% year-over-year, even as Wellspect Healthcare expanded 7.1%. Management maintained full-year revenue targets of $3.5 billion to $3.6 billion and EPS of $1.40 to $1.50.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “DENTSPLY SIRONA Beats Q2 Adjusted EPS at $0.52 and Reaffirms Guidance”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-beats-q2-adjusted-eps-at-0-52-and-reaffirms-guidance-e7f83a

    EQUITY
    DENTSPLY SIRONA Beats Q2 Adjusted EPS at $0.52 and Reaffirms Guidance
    DENTSPLY SIRONA delivered a solid bottom-line performance in Q2, with adjusted EPS reaching $0.52 against the $0.36 expected by analysts. Cost controls and segment performance bolstered profitability. Consolidated revenue contracted by 4.1% year-over-year, even as Wellspect Healthcare expanded 7.1%. Management maintained full-year revenue targets of $3.5 billion to $3.6 billion and EPS of $1.40 to $1.50.
    XRAY
    Impact
    65
    SEP 9
    SIG
    85%
    XRAY
    DENTSPLY SIRONA Beats Q2 Adjusted EPS at $0.52 and Reaffirms Guidance
    DENTSPLY SIRONA delivered a solid bottom-line performance in Q2, with adjusted EPS reaching $0.52 against the $0.36 expected by analysts. Cost controls and segment performance bolstered profitability. Consolidated revenue contracted by 4.1% year-over-year, even as Wellspect Healthcare expanded 7.1%. Management maintained full-year revenue targets of $3.5 billion to $3.6 billion and EPS of $1.40 to $1.50.
    → Segment margin strength in Wellspect offsets a 4.1% revenue decline, securing full-year adjusted EPS guidance of $1.40-$1.50 for XRAY.
    Impact
    DENTSPLY SIRONA delivered a solid bottom-line performance in Q2, with adjusted EPS reaching $0.52 against the $0.36 expected by analysts. Cost controls and segment performance bolstered profitability. Consolidated revenue contracted by 4.1% year-over-year, even as Wellspect Healthcare expanded 7.1%. Management maintained full-year revenue targets of $3.5 billion to $3.6 billion and EPS of $1.40 to $1.50.
    Affected
    XRAY
    Transmission
    Segment margin strength in Wellspect offsets a 4.1% revenue decline, securing full-year adjusted EPS guidance of $1.40-$1.50 for XRAY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYearnings beat pass-through to equity valuationUp1-5dQ2 adjusted EPS of $0.52 topped consensus of $0.36 while FY2026 guidance of $1.40-$1.50 was reaffirmed.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYUpdisagreed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month